Compare CWCO & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | LAB |
|---|---|---|
| Founded | 1973 | 1999 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.2M | 488.4M |
| IPO Year | 1997 | 2008 |
| Metric | CWCO | LAB |
|---|---|---|
| Price | $34.55 | $0.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $1.35 |
| AVG Volume (30 Days) | 82.6K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ 44.68 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $133,966,633.00 | $101,937,000.00 |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $37.71 | $2.63 |
| P/E Ratio | $35.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.69 | $0.92 |
| 52 Week High | $39.12 | $1.72 |
| Indicator | CWCO | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 23.76 |
| Support Level | $34.37 | N/A |
| Resistance Level | $34.66 | $1.41 |
| Average True Range (ATR) | 1.10 | 0.07 |
| MACD | -0.39 | -0.01 |
| Stochastic Oscillator | 15.52 | 3.02 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.